Anthera announces positive Phase II clinical results from A-002 cardiovascular disease trial
Anthera Pharmaceuticals, Inc., a privately-held biopharmaceutical company, reported results of a Phase II clinical trial of its first compound, A- 002, for the treatment of cardiovascular disease. The trial results suggest that treatment with A- 002 resulted in significant reductions in blood levels of total cholesterol, Non-High Density Lipoprotein Cholesterol (non HDL-C), and Low Density Lipoprotein Cholesterol (LDL-C), known as “bad” cholesterol, coupled with equally meaningful reductions of C-Reactive Protein (CRP), a recognized marker of inflammation and cardiovascular risk. Decreases in these levels with A- 002 treatment were most significant among patients already on a background of statin therapy.
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.